HIV RAPID TESTING AMONG SUBSTANCE ABUSERS

对药物滥用者进行艾滋病毒快速检测

• 批准号: 6283554
• 负责人: Michelle A Lally
• 金额: $ 6.96万
• 依托单位: MIRIAM HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-09-30 至 2002-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6283554
• 关键词: AIDS /HIV test; clinical research; computer assisted patient care; disease /disorder proneness /risk; drug abuse chemotherapy; high risk behavior /lifestyle; human subject; interview; intravenous drug abuse; rapid diagnosis; satisfaction; sex behavior; substance abuse related disorder

This application is a request for an RO3 award from NIMH to evaluate the acceptability and feasibility of rapid testing for HIV among substance abusers. Dr. Lally is in her second year on the full time faculty as an Assistant Professor of Medicine at Brown University. The clinical research training environment at the Miriam Hospital and Brown University is well-suited for an RO3. Substance abusers are at high risk for HIV disease not only because of needle sharing and "sharing of works" associated with injection drug use, but also because of high-risk sexual behavior among active substance abusers. Short-term substance abuse treatment (detoxification) is an excellent opportunity to interface with active substance abusers both for diagnosis of disease and linkage to medical care. Testing for HIV is not routinely offered at most detoxification centers. In contrast, we have routinely offered standard two visit HIV testing to inpatients at detoxification centers in Rhode Island and have found testing to be well received. Follow-up for HIV test results is a problem nation wide, and new technology now makes it possible to do rapid HIV testing so that immediate results are available. Quix(TM) is a rapid HIV test that can be easily administered in the detoxification setting. Feasibility and acceptability of rapid testing in this setting will be evaluated. We will administer an ACASI risk assessment to all study participants and then offer them HIV testing with both the rapid test, Quix(TM), and the standard FDA approved Orasure(R) test. We will test 220 people -55 young women (18-25), 55 older women (>25), 55 young men (18-25), and 55 older men (>25)- who are inpatients at a substance abuse detoxification center. Participants will be provided with their test results from the Quix(TM) test within minutes, and they will also be encouraged to receive the results of their Orasure(R) tests, which generally will be available within 2-3 days. Acceptability and satisfaction of rapid compared to standard testing as well as follow up rates will be evaluated among younger and older men and women and by risk profile.

这项申请是为了申请NIMH颁发的R03奖，以评估药物滥用者对艾滋病毒快速检测的可接受性和可行性。拉利博士在布朗大学担任医学助理教授，是她全职教职的第二年。米里亚姆医院和布朗大学的临床研究培训环境非常适合RO。药物滥用者感染艾滋病毒的风险很高，这不仅是因为与注射毒品有关的共用针头和“共用工作”，也是因为活性物质滥用者之间的高危性行为。短期药物滥用治疗(戒毒)是与活跃的药物滥用者接触的绝佳机会，既可以诊断疾病，也可以与医疗保健联系起来。大多数戒毒中心都不会常规提供艾滋病毒检测。相比之下，我们经常向罗德岛戒毒中心的住院患者提供标准的两次访问艾滋病毒检测，并发现检测结果很受欢迎。对艾滋病毒检测结果的跟踪是一个全国性的问题，新技术现在使快速进行艾滋病毒检测成为可能，以便立即获得结果。Quix(TM)是一种可以在戒毒环境中轻松实施的快速艾滋病毒检测方法。将评估快速检测在这种情况下的可行性和可接受性。我们将对所有研究参与者进行ACASI风险评估，然后用快速测试Quix(TM)和FDA批准的标准Orasure(R)测试为他们提供艾滋病毒检测。我们将测试220人--55名年轻女性(18-25岁)、55名老年女性(&gt；25)、55名年轻男性(18-25岁)和55名老年男性(&gt；25)--他们是药物滥用戒毒中心的住院患者。参与者将在几分钟内收到他们的Quix(商标)测试结果，他们还将被鼓励收到他们的Orasure(R)测试结果，这些结果通常将在2-3天内公布。将评估年轻和老年男性和女性对快速检测与标准检测的可接受性和满意度以及随访率，并根据风险状况进行评估。